Key Insights Intellia Therapeutics will host its Annual General Meeting on 12th of June CEO John Leonard's total...
Intellia (NTLA) gains 10% after reporting encouraging long-term efficacy data from the phase I portion of its early to mid-stage study evaluating NTLA-2002 for treating hereditary angioedema.
We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss whether Intellia Therapeutics, Inc. (NASDAQ:NTLA) is the most promising gene therapy stock to buy now. Gene therapy involves treating illnesses by modifying, replacing, or supplementing faulty or missing genes responsible for a disease. This […]